Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

9.380 +0.310 (+3.42%)

Streaming Delayed Price Updated: 3:59 PM EST, Nov 17, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	41,908
Open	9.070
Bid (Size)	9.100 (100)
Ask (Size)	9.540 (200)
Prev. Close	9.070
Today's Range	9.070 - 9.750
52wk Range	5.349 - 13.65
Shares Outstanding	11,586,406
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

November 05, 2025

From Tempest Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 17, 2025

Via Benzinga

Performance

YTD	-15.9%	-15.9%
1 Month	-10.9%	-10.9%
3 Month	-7.7%	-7.7%
6 Month	+40.8%	+40.8%
1 Year	-14.9%	-14.9%

More News

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 04, 2025

Via Benzinga

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 30, 2025

From Tempest Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 11, 2025

Via Benzinga

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025

From Tempest Therapeutics

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

June 09, 2025

Via Chartmill

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

June 09, 2025

Via Benzinga

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 09, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 09, 2025

Via Benzinga

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 05, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

April 21, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗

April 10, 2025

Via Benzinga

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger ↗

April 10, 2025

Via Stocktwits

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

April 09, 2025

From Tempest Therapeutics

Via GlobeNewswire

Monday's session: gap up and gap down stocks ↗

April 07, 2025

Via Chartmill

Tempest Reports Year End 2024 Financial Results and Provides Business Update

March 27, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

March 25, 2025

From Tempest Therapeutics

Via GlobeNewswire

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

March 13, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tuesday's after hours session: top gainers and losers ↗

March 04, 2025

Via Chartmill

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

February 10, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 07, 2025

From Tempest Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Tempest Therapeutics, Inc. - Common Stock publicly traded?

Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?

Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?

The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market

What is the current price of Tempest Therapeutics, Inc. - Common Stock?

The current price of Tempest Therapeutics, Inc. - Common Stock is 9.380

When was Tempest Therapeutics, Inc. - Common Stock last traded?

The last trade of Tempest Therapeutics, Inc. - Common Stock was at 11/17/25 03:59 PM ET

What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?

The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 108.68M

How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?

Tempest Therapeutics, Inc. - Common Stock has 109M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.